Johnson & Johnson $JNJ Shares Sold by Cullen Capital Management LLC

Cullen Capital Management LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,211,617 shares of the company’s stock after selling 23,269 shares during the period. Johnson & Johnson makes up about 2.1% of Cullen Capital Management LLC’s investment portfolio, making the stock its 18th largest position. Cullen Capital Management LLC owned approximately 0.05% of Johnson & Johnson worth $185,074,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in JNJ. Summit Financial Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 4.4% in the 2nd quarter. Summit Financial Wealth Advisors LLC now owns 6,478 shares of the company’s stock worth $990,000 after purchasing an additional 271 shares in the last quarter. Capital A Wealth Management LLC grew its position in Johnson & Johnson by 20.3% in the second quarter. Capital A Wealth Management LLC now owns 426 shares of the company’s stock worth $67,000 after buying an additional 72 shares during the last quarter. Caldwell Trust Co bought a new position in shares of Johnson & Johnson in the second quarter valued at $9,052,000. Canal Capital Management LLC lifted its position in shares of Johnson & Johnson by 3.7% during the 2nd quarter. Canal Capital Management LLC now owns 49,733 shares of the company’s stock valued at $7,597,000 after acquiring an additional 1,783 shares during the last quarter. Finally, Milestones Private Investment Advisors LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth $318,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $214.41 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm has a market capitalization of $516.58 billion, a price-to-earnings ratio of 20.70, a price-to-earnings-growth ratio of 2.36 and a beta of 0.36. The company has a 50 day simple moving average of $196.61 and a 200-day simple moving average of $177.85. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $215.19.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Analyst Ratings Changes

Several brokerages have recently commented on JNJ. Sanford C. Bernstein upped their target price on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday. Bank of America raised their target price on shares of Johnson & Johnson from $204.00 to $220.00 and gave the stock a “neutral” rating in a report on Monday. UBS Group boosted their price target on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Finally, Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $208.35.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.